{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:32:24Z","timestamp":1790094744567,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"name":"Ankara Child Health Hematology-Oncology Training and Research Hospital research grant","award":["2019-042"],"award-info":[{"award-number":["2019-042"]}]},{"DOI":"10.13039\/501100014801","name":"Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study aims to determine the role of urinary plasminogen, a serine protease that reflects damage to the glomerular filtration barrier, in the early detection of diabetic kidney disease in pediatric patients with type 1 diabetes mellitus (T1DM).\u00a0Pediatric patients, who had been followed up with T1DM for at least 2\u00a0years, and healthy matched controls were included. The association between urine plasminogen (uPlasminogen) levels and urine plasminogen-to-creatinine ratio (uPlgCR) with urine albumin-to-creatinine ratio (uACR) was examined, as well as determining a cut-off value for uPlasminogen to predict microalbuminuria. A total of\u00a056 T1DM patients and 30 healthy matched controls were included. There was no significant difference in eGFR (estimated glomerular filtration rate) and systolic and diastolic blood pressure between the groups. uPlasminogen level was determined to be higher in the albuminuric group than control (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and uPlgCR was higher in the normoalbuminuric and albuminuric groups than control (<jats:italic>p<\/jats:italic>\u2009=\u20090.004, <jats:italic>p<\/jats:italic>\u2009=\u20090.002, respectively). There was a weak positive correlation between uPlasminogen and uPlgCR with uACR (<jats:italic>r<\/jats:italic> 0.38,<jats:italic> p<\/jats:italic>\u2009=\u20090.004; <jats:italic>r<\/jats:italic> 0.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.03, respectively). The diagnostic performance of uPlasminogen in predicting albuminuria was evaluated by ROC-curve analysis, showing an AUC of 0.69 (<jats:italic>p<\/jats:italic>\u2009=\u20090.02; 95% CI [0.521\u20130.861]), with a sensitivity of 75% and specificity of 65.5% at a cut-off value of 7.1\u00a0\u00b5g\/L. <jats:italic>Conclusion:\u00a0<\/jats:italic>A positive correlation was found between uPlasminogen and uPlgCR with albuminuria. Also, uPlasminogen was determined to predict albuminuria. Most importantly, uPlgCR was elevated in diabetic patients before albuminuria developed. uPlgCR may serve as a potential early marker or therapeutic target of DKD, pending further longitudinal validation.\n<jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is Known:<\/jats:bold>\u2022 <jats:italic>Urinary plasminogen correlates with albuminuria in diabetic patients.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is New:<\/jats:bold>\u2022 <jats:italic>Urinary plasminogen and uPlgCR levels exhibited a significant and positive correlation with uACR. The new findings in this study are that uPlgCR was detected in urine before microalbuminuria develops, and that uPlasminogen predicted albuminuria in pediatric patients with T1DM.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:p>","DOI":"10.1007\/s00431-025-06278-3","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:04:45Z","timestamp":1750982685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Urinary plasminogen as an early marker of diabetic kidney disease in children with type 1 diabetes mellitus: a cross-sectional study"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7337","authenticated-orcid":false,"given":"Mihriban","family":"\u0130n\u00f6z\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-7295","authenticated-orcid":false,"given":"G\u00f6n\u00fcl","family":"B\u00fcy\u00fcky\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-379X","authenticated-orcid":false,"given":"Beg\u00fcm","family":"Avc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-3508","authenticated-orcid":false,"given":"\u0130smail Sel\u00e7uk","family":"Aygar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-275X","authenticated-orcid":false,"given":"Fatma Semsa","family":"\u00c7ayc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-4454","authenticated-orcid":false,"given":"Seyit Ahmet","family":"U\u00e7akt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1597-8418","authenticated-orcid":false,"given":"Eda","family":"Mengen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-1511","authenticated-orcid":false,"given":"Sare G\u00fclfem","family":"\u00d6zl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-2617","authenticated-orcid":false,"given":"Umut Selda","family":"Bayrak\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"6278_CR1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651\u20131658. https:\/\/doi.org\/10.2337\/db08-1543","journal-title":"Diabetes"},{"key":"6278_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/pedi.13444","volume":"23","author":"P Bjornstad","year":"2022","unstructured":"Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, Wadwa RP, Zabeen B, Marcovecchio ML (2022) ISPAD Clinical Practice Consensus Guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes 23:1432\u20131450. https:\/\/doi.org\/10.1111\/pedi.13444","journal-title":"Pediatr Diabetes"},{"key":"6278_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s0140-6736(95)91747-0","volume":"346","author":"CE Mogensen","year":"1995","unstructured":"Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080\u20131084. https:\/\/doi.org\/10.1016\/s0140-6736(95)91747-0","journal-title":"Lancet"},{"key":"6278_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00467-014-2888-2","volume":"30","author":"SY Lee","year":"2015","unstructured":"Lee SY, Choi ME (2015) Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol 30:1063\u20131075. https:\/\/doi.org\/10.1007\/s00467-014-2888-2","journal-title":"Pediatr Nephrol"},{"key":"6278_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/ndt\/gfu402","volume":"30","author":"H Andersen","year":"2015","unstructured":"Andersen H, Friis UG, Hansen PB, Svenningsen P, Henriksen JE, Jensen BL (2015) Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells. Nephrol Dial Transplant 30:781\u2013789. https:\/\/doi.org\/10.1093\/ndt\/gfu402","journal-title":"Nephrol Dial Transplant"},{"key":"6278_CR6","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.1111\/apha.13249","volume":"225","author":"F Artunc","year":"2019","unstructured":"Artunc F, Worn M, Schork A, Bohnert BN (2019) Proteasuria-the impact of active urinary proteases on sodium retention in nephrotic syndrome. Acta Physiol (Oxf) 225:e13249. https:\/\/doi.org\/10.1111\/apha.13249","journal-title":"Acta Physiol (Oxf)"},{"key":"6278_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ekir.2018.06.007","volume":"3","author":"EC Ray","year":"2018","unstructured":"Ray EC, Miller RG, Demko JE, Costacou T, Kinlough CL, Demko CL, Unruh ML, Orchard TJ, Kleyman TR (2018) Urinary plasmin(ogen) as a prognostic factor for hypertension. Kidney Int Rep 3:1434\u20131442. https:\/\/doi.org\/10.1016\/j.ekir.2018.06.007","journal-title":"Kidney Int Rep"},{"key":"6278_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/HYPERTENSIONAHA.112.198879","volume":"60","author":"KB Buhl","year":"2012","unstructured":"Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Moller B, Jespersen B, Bistrup C, Jensen BL (2012) Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension 60:1346\u20131351. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.198879","journal-title":"Hypertension"},{"key":"6278_CR9","doi-asserted-by":"publisher","unstructured":"Buhl KB, Oxlund CS, Friis UG, Svenningsen P, Bistrup C, Jacobsen IA, Jensen BL (2014) Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. J Hypertens 32:1672\u20131677; discussion 1677. https:\/\/doi.org\/10.1097\/HJH.0000000000000216","DOI":"10.1097\/HJH.0000000000000216"},{"key":"6278_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.2008040364","volume":"20","author":"P Svenningsen","year":"2009","unstructured":"Svenningsen P, Bistrup C, Friis UG et al (2009) Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 20:299\u2013310. https:\/\/doi.org\/10.1681\/ASN.2008040364","journal-title":"J Am Soc Nephrol"},{"key":"6278_CR11","doi-asserted-by":"publisher","first-page":"F480","DOI":"10.1152\/ajprenal.00199.2021","volume":"321","author":"BN Bohnert","year":"2021","unstructured":"Bohnert BN, Essigke D, Janessa A et al (2021) Experimental nephrotic syndrome leads to proteolytic activation of the epithelial Na(+) channel in the mouse kidney. Am J Physiol Renal Physiol 321:F480\u2013F493. https:\/\/doi.org\/10.1152\/ajprenal.00199.2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"6278_CR12","doi-asserted-by":"publisher","first-page":"36586","DOI":"10.1074\/jbc.M805676200","volume":"283","author":"CJ Passero","year":"2008","unstructured":"Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, Kleyman TR (2008) Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J Biol Chem 283:36586\u201336591. https:\/\/doi.org\/10.1074\/jbc.M805676200","journal-title":"J Biol Chem"},{"key":"6278_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4274\/jcrpe.4526","volume":"9","author":"K Demir","year":"2017","unstructured":"Demir K, Ozen S, Konakci E, Aydin M, Darendeliler F (2017) A comprehensive online calculator for pediatric endocrinologists: CEDD Cozum\/TPEDS Metrics. J Clin Res Pediatr Endocrinol 9:182\u2013184. https:\/\/doi.org\/10.4274\/jcrpe.4526","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"6278_CR14","unstructured":"https:\/\/www.cloud-clone.com\/products\/SEB236Hu.html(April 2019) In."},{"key":"6278_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6278_CR16","doi-asserted-by":"publisher","unstructured":"KDOQI (2007) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S12-154. https:\/\/doi.org\/10.1053\/j.ajkd.2006.12.005","DOI":"10.1053\/j.ajkd.2006.12.005"},{"key":"6278_CR17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00467-013-2439-2","volume":"28","author":"RF Andersen","year":"2013","unstructured":"Andersen RF, Buhl KB, Jensen BL, Svenningsen P, Friis UG, Jespersen B, Rittig S (2013) Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol 28:1227\u20131234. https:\/\/doi.org\/10.1007\/s00467-013-2439-2","journal-title":"Pediatr Nephrol"},{"key":"6278_CR18","doi-asserted-by":"publisher","first-page":"18831","DOI":"10.1074\/jbc.M111.323287","volume":"287","author":"D Barthel","year":"2012","unstructured":"Barthel D, Schindler S, Zipfel PF (2012) Plasminogen is a complement inhibitor. J Biol Chem 287:18831\u201318842. https:\/\/doi.org\/10.1074\/jbc.M111.323287","journal-title":"J Biol Chem"},{"key":"6278_CR19","doi-asserted-by":"publisher","unstructured":"Bae J, Won YJ, Lee BW (2021) Non-albumin proteinuria (NAP) as a complementary marker for diabetic kidney disease (DKD). Life (Basel) 11. https:\/\/doi.org\/10.3390\/life11030224","DOI":"10.3390\/life11030224"},{"key":"6278_CR20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","volume":"56","author":"RE Gilbert","year":"1999","unstructured":"Gilbert RE, Cooper ME (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56:1627\u20131637. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00721.x","journal-title":"Kidney Int"},{"key":"6278_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2337\/db16-0796","volume":"66","author":"RE Gilbert","year":"2017","unstructured":"Gilbert RE (2017) Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes 66:791\u2013800. https:\/\/doi.org\/10.2337\/db16-0796","journal-title":"Diabetes"},{"key":"6278_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1681\/ASN.2005010089","volume":"17","author":"JJ Roelofs","year":"2006","unstructured":"Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S (2006) Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 17:131\u2013140. https:\/\/doi.org\/10.1681\/ASN.2005010089","journal-title":"J Am Soc Nephrol"},{"key":"6278_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF01235631","volume":"8","author":"R Osterby","year":"1972","unstructured":"Osterby R (1972) Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes. I. Development of initial basement membrane thickening. Diabetologia 8:84\u201392. https:\/\/doi.org\/10.1007\/BF01235631","journal-title":"Diabetologia"},{"key":"6278_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI111523","volume":"74","author":"SM Mauer","year":"1984","unstructured":"Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143\u20131155. https:\/\/doi.org\/10.1172\/JCI111523","journal-title":"J Clin Invest"},{"key":"6278_CR25","doi-asserted-by":"publisher","unstructured":"Afkarian M (2015) Diabetic kidney disease in children and adolescents. Pediatr Nephrol 30:65\u201374; quiz 70\u201361. https:\/\/doi.org\/10.1007\/s00467-014-2796-5","DOI":"10.1007\/s00467-014-2796-5"},{"key":"6278_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10157-020-01881-0","volume":"24","author":"M Yamanouchi","year":"2020","unstructured":"Yamanouchi M, Furuichi K, Hoshino J, Ubara Y, Wada T (2020) Nonproteinuric diabetic kidney disease. Clin Exp Nephrol 24:573\u2013581. https:\/\/doi.org\/10.1007\/s10157-020-01881-0","journal-title":"Clin Exp Nephrol"},{"key":"6278_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ki.2009.399","volume":"77","author":"BA Perkins","year":"2010","unstructured":"Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS (2010) In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77:57\u201364. https:\/\/doi.org\/10.1038\/ki.2009.399","journal-title":"Kidney Int"},{"key":"6278_CR28","doi-asserted-by":"publisher","first-page":"16191","DOI":"10.1096\/fj.202000413R","volume":"34","author":"MA Egerman","year":"2020","unstructured":"Egerman MA, Wong JS, Runxia T et al (2020) Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease. FASEB J 34:16191\u201316204. https:\/\/doi.org\/10.1096\/fj.202000413R","journal-title":"FASEB J"},{"issue":"205\u2013214","key":"6278_CR29","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1053\/j.ajkd.2024.01.520","volume":"84","author":"M de Cos","year":"2024","unstructured":"de Cos M, Mosoyan G, Chauhan K et al (2024) Urinary plasminogen as a marker of disease progression in human glomerular disease. Am J Kidney Dis 84(205\u2013214):e201. https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.520","journal-title":"Am J Kidney Dis"},{"key":"6278_CR30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00424-017-2014-y","volume":"469","author":"P Svenningsen","year":"2017","unstructured":"Svenningsen P, Hinrichs GR, Zachar R, Ydegaard R, Jensen BL (2017) Physiology and pathophysiology of the plasminogen system in the kidney. Pflugers Arch 469:1415\u20131423. https:\/\/doi.org\/10.1007\/s00424-017-2014-y","journal-title":"Pflugers Arch"},{"key":"6278_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00431-025-06040-9","volume":"184","author":"L Dato","year":"2025","unstructured":"Dato L, Mancuso MC, Ria T et al (2025) Multiple office blood pressure monitoring for the diagnosis of hypertension in children. Eur J Pediatr 184:213. https:\/\/doi.org\/10.1007\/s00431-025-06040-9","journal-title":"Eur J Pediatr"},{"key":"6278_CR32","doi-asserted-by":"publisher","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140. https:\/\/doi.org\/10.1542\/peds.2017-1904","DOI":"10.1542\/peds.2017-1904"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:12:48Z","timestamp":1753279968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06278-3","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of our hospital (date 25 March 2019\/approval no: 042). The study involving human participants was performed in accordance with the Declaration of Helsinki, and the study protocol was approved by the Medical Research Ethics Committee of Ankara Child Health Hematology-Oncology Training and Research Hospital (Protocol Number: 2019\u2013042).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants and their parents included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"451"}}